A targeted, specifically engineered exosome containing Hylton alcohol (a toll-like receptor 3 [TLR3] activator) and the immunogenic cell death-inducer human neutrophil elastase (ELANE) has been developed and optimized to form an in situ DC vaccine for breast cancer treatment, enhancing antitumor immunity against breast cancer (56). This evidence concerns the gene ELANE and breast carcinoma.